International journal of clinical practice
-
Int. J. Clin. Pract. · Dec 2021
Randomized Controlled Trial Multicenter Study Controlled Clinical TrialGender, age, disease severity, body mass index, and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials.
To assess the impact of pre-specified patient characteristics on efficacy and safety of subcutaneous tanezumab in patients with osteoarthritis (OA). ⋯ Efficacy and safety/tolerability of tanezumab may not be meaningfully impacted by gender, age, BMI, diabetes status, baseline pain severity or KL grade in the index joint. Conclusions are limited by low patient number in some subgroups. Clinicaltrials.gov: NCT02697773, NCT02709486, NCT01089725.
-
Int. J. Clin. Pract. · Dec 2021
Meta AnalysisTotal and drinking water intake and risk of all-cause and cardiovascular mortality: a systematic review and dose-response meta-analysis of prospective cohort studies.
Understanding the association between water consumption and mortality is important for guiding consumers and prioritizing dietary guidelines to reduce the risk. Therefore, in the current study, we conducted a systematic review and dose-response meta-analysis of prospective cohort studies to summarise the association between total water and drinking intake and risk of mortality from all causes and CVD. ⋯ High consumption of total water is associated with a lower risk of CVD mortality. However, total water intake was not associated with risk of all-cause mortality.
-
Int. J. Clin. Pract. · Dec 2021
The Relationship between CRP at Admission and Thorax CT Findings in Patients Diagnosed with COVID-19.
The current study aims to evaluate the relationship between C-reactive protein (CRP) levels, thorax CT findings and CT-SS in patients presenting to the emergency department with COVID-19. ⋯ The CRP levels of COVID-19 patients measured upon admission to the emergency room are correlated with the severity of lung involvement and are an important predictor of clinical outcomes.
-
Int. J. Clin. Pract. · Dec 2021
Meta AnalysisExploration of severe Covid-19 associated risk factor in China: meta-analysis of current evidence.
This meta-analysis aimed to explore potential risk factors for severe Covid-19. ⋯ There are significant differences in clinical characteristics between the severe and non-severe Covid-19 patients. Many factors are related to the severity of the disease, which can help clinicians to differentiate severe patients from non-severe patients.
-
Int. J. Clin. Pract. · Dec 2021
Multicenter StudySafety and efficacy of alirocumab in real life setting: analysis of the Belgian cohort of the ODYSSEY APPRISE trial with review of current lipid treatment guidelines and its implementation in clinical practice.
As lipid targets became more stringent in the latest ESC/EAS guidelines, many patients on statin monotherapy are left above their risk-based target, increasing the need for lipid-lowering therapies. The results of the ODYSSEY APPRISE study were recently published by Gaudet et al In this trial, alirocumab (a PCSK9 inhibitor) was investigated in high cardiovascular risk patients in a real-life setting. ⋯ In a real-life setting, alirocumab is both well-tolerated, safe and very effective in reducing LDL-c in this Belgian cohort. In clinical practice, more patients should be initiated on the add-on, non-statin lipid-lowering therapy in order to reach their risk-based lipid target.